Jingui Xu

ORCID: 0009-0002-8180-4213
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Uterine Myomas and Treatments
  • Microtubule and mitosis dynamics
  • Enhanced Recovery After Surgery
  • Abdominal Surgery and Complications
  • Endometriosis Research and Treatment
  • Cardiac, Anesthesia and Surgical Outcomes
  • Intestinal and Peritoneal Adhesions
  • Genetic and Kidney Cyst Diseases
  • Cancer-related Molecular Pathways
  • Cytomegalovirus and herpesvirus research
  • X-ray Diffraction in Crystallography
  • Epigenetics and DNA Methylation
  • Geological and Geochemical Analysis
  • Ubiquitin and proteasome pathways
  • Maternal and Perinatal Health Interventions
  • Cancer, Hypoxia, and Metabolism
  • Reproductive Health and Contraception
  • Endometrial and Cervical Cancer Treatments
  • High-pressure geophysics and materials
  • Medical Research and Treatments
  • RNA Research and Splicing
  • Asian Culture and Media Studies
  • Assisted Reproductive Technology and Twin Pregnancy

Quzhou City People's Hospital
2005-2025

Wenzhou Medical University
2021-2025

University of Hawaiʻi at Mānoa
2022

Quzhou College of Technology
2012

Abstract Endometrial cancer (EC), as one of the most common cancers, severely threatens female reproductive health. Our previous study has shown that Kinesin family member C1 (KIFC1) played crucial roles in progression EC. In addition, abnormal centrosome amplification, which was reported to be partially regulated by KIFC1, usually occurred different cancers. However, whether KIFC1 promoted EC through amplification and potential mechanism remain revealed. The present demonstrated...

10.1038/s41420-024-02190-1 article EN cc-by Cell Death Discovery 2024-09-30

Importance Adenomyosis is a common chronic gynecological disorder, and its treatment an unmet need. New therapies need to be developed. Mifepristone being tested for adenomyosis treatment. Objective To determine whether mifepristone effective safe Design, Setting, Participants This multicenter, placebo-controlled, double-blind randomized clinical trial was conducted in 10 hospitals China. In total, 134 patients with pain symptoms were enrolled. Trial enrollment began May 2018 completed April...

10.1001/jamanetworkopen.2023.17860 article EN cc-by-nc-nd JAMA Network Open 2023-06-12

Endometrial cancer (EC) is one of the most common cancers among women worldwide. Kinesin family member C1 (KIFC1) has been demonstrated to play crucial roles in various tumors. However, function KIFC1 EC remains be revealed. In this study, upregulation expression human tissues was found from analysis on data The Cancer Genome Atlas (TCGA), and positively correlated with short survival outcome patients. addition, mRNA protein levels were confirmed up-regulated cells (Ishikawa, HEC-1B, HEC-1A...

10.1177/1533033820964217 article EN cc-by-nc Technology in Cancer Research & Treatment 2020-01-01

Advances in surgical techniques and perioperative management are the two major contributing factors to improved outcomes. The purpose of current study was compare efficacy single-port surgery enhanced recovery after (ERAS) laparoscopic myomectomy.The present included 120 patients undergoing myomectomy Gynecological Ward Quzhou Affiliated Hospital Wenzhou Medical University. According traditional mode ERAS management, multi-port procedures, all were assigned Conventional-SPLS (Single-Port...

10.1186/s12905-023-02550-6 article EN cc-by BMC Women s Health 2023-08-01

Abstract Objective: Advances in surgical techniques and perioperative management are the two major contributing factors to improved outcomes. The purpose of current study was compare efficacy single-port surgery enhanced recovery after (ERAS) laparoscopic myomectomy. Methods : present included 120 patients undergoing myomectomy Gynecological Ward Quzhou Affiliated Hospital Wenzhou Medical University. According traditional mode ERAS management, multi-port procedures, all were assigned...

10.21203/rs.3.rs-2680570/v1 preprint EN cc-by Research Square (Research Square) 2023-03-30

Background: Despite advancements in drug therapy, many patients with adenomyosis fail to achieve treatment goals. Therefore, new therapies need be developed. Our aim was evaluate the efficacy, safety and tolerability of mifepristone versus placebo painful adenomyosis.Methods: We conducted a randomized, multicenter, double-blind placebo-controlled trial 10 hospitals China. Eligible were randomly assigned 1:1 ratio receive or orally once day for 12 weeks. The randomization sequence generated...

10.2139/ssrn.3897694 article EN SSRN Electronic Journal 2021-01-01
Coming Soon ...